PRNEWSWIRE CAMBRIDGE, Massachusetts, November 4 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration... [read full story]
|
RELATED
|
|
By Christine McConville Wednesday, November 4, 2009 - Added 2m ago The U.S. Food and Drug Administration will fast-track its review of Shire PLC’s treatment for Gaucher disease, the Cambridge biotechnology company announced...
Associated Press Shire PLC said that the Food and Drug Administration granted the company's developing treatment for Gaucher disease a priority review. Gaucher disease is a rare enzyme disorder that can cause liver and...
CAMBRIDGE, Massachusetts, November 4 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review...
Shire plc , the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the...
Learning Disorders, Genetics and Birth Defects, Mental Health & Behavior, Pharmaceuticals, Ambulatory Health Care, Child Health, Medicines & Remedies, Scientific Discoveries, Health Care, Biopharmaceuticals, Attention Deficit Disorder, Patients, Medical Research, Shire, Massachusetts, United States of America, North America, Cambridge (Massachusetts)
